Taysha Gene Therapies, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
TSHA$4.33+5.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
| For the three months ended June 30, | For the six months ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue | $— | $1,986 | $— | $4,288 |
| Operating expenses: | ||||
| Research and development | 38,636 | 20,141 | 72,445 | 35,706 |
| General and administrative | 12,146 | 8,598 | 21,823 | 16,756 |
| Net gain on lease termination | (3,433) | — | (3,433) | — |
| Total operating expenses | 47,349 | 28,739 | 90,835 | 52,462 |
| Loss from operations | (47,349) | (26,753) | (90,835) | (48,174) |
| Other income (expense): | ||||
| Change in fair value of warrant liability | — | (273) | — | (171) |
| Change in fair value of term loan | (1,521) | (1,461) | (2,991) | (2,991) |
| Interest income | 2,325 | 1,859 | 4,911 | 3,185 |
| Interest expense | (6) | (17) | (15) | (36) |
| Other expense | (88) | (237) | (119) | (224) |
| Total other income (expense), net | 710 | (129) | 1,786 | (237) |
| Net loss | $(46,639) | $(26,882) | $(89,049) | $(48,411) |
| Net loss per common share, basic and diluted | $(0.13) | $(0.09) | $(0.24) | $(0.17) |
| Weighted average common shares outstanding, basic and diluted | 369,044,040 | 297,988,978 | 367,845,094 | 283,726,888 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.